Open Access

The KT Jeang Retrovirology prize 2016: Frank Kirchhoff

Retrovirology201613:53

https://doi.org/10.1186/s12977-016-0286-5

Received: 18 July 2016

Accepted: 18 July 2016

Published: 5 August 2016

The Erratum to this article has been published in Retrovirology 2016 13:69

Frank Kirchhoff studied Biology at the Georg August-University in Göttingen and performed his diploma and PhD thesis at the German Primate Center under the supervision of Gerhard Hunsmann. The main goal of his thesis was the generation of a novel molecular clone of HIV-2 from an infected cell culture. After a challenging start involving the screening of millions of bacteriophage lambda plaques and the repeated isolation of only the 5′-half of the viral genome, he finally succeeded in cloning and characterizing the full-length infectious molecular clone of HIV-2 BEN [1, 2].

After graduation in 1991, Kirchhoff obtained a fellowship from the German Ministry of Health and joined Ronald C. Desrosiers’ group at the New England Regional Primate Research Center (Harvard Med. School, Southboro) for postdoctoral studies. Initially, he worked on the envelope glycoprotein of SIV and showed that the V3 loop region of SIVmac Env determines the viral coreceptor tropism [3] and functionally cooperates with the C4 region [4]. Kirchhoff was also part of a pioneering study showing that live-attenuated nef-deleted SIVmac239 efficiently protects rhesus macaques against challenge with pathogenic wild-type virus [5]. Initially, all his attempts to detect the vaccine or wild-type viruses in these animals by PCR failed, raising strong doubts about his ability to perform this “novel” technique. Later, it turned out that nef-deleted SIVmac strains lose large parts of their LTR (including some selected primer binding sites) because they serve mainly as nef coding sequences in vivo [6]. Another exciting finding also involved PCR: just before starting a new position in Germany, he obtained evidence for the long-sought after presence of defective nef genes in a long-term survivor of HIV-1 infection. Thus, after signing his contract in Germany he moved back to the US for a couple of months to characterize the first described long-term survivor infected by a nef-deleted HIV-1 strain [7].

In 1994, Kirchhoff established an independent research group at the Institute of Clinical and Molecular Virology (University of Erlangen) under the directorship of Bernhard Fleckenstein. He maintained an interest in Env function and HIV entry. Together with Stefan Pöhlmann, his first student as independent researcher (who became the successor of Kirchhoff`s first boss, Gerhard Hunsmann, ~15 years later), he analyzed the utilization of alternative coreceptors, such as BOB/GPR-15 and BONZO/STRL-33, by HIV-1 and SIVmac [811]. In cooperation with Robert Doms, he also examined the mechanisms underlying the interaction of HIV-1 with DC-SIGN and showed that virus binding and transfer are separable activities [12, 13]. Kirchhoff further continued collaborating with Jacek Skowronski, John L. Sullivan and Thomas C. Greenough to identify another long-term survivor with HIV-1 infection harboring defective nef alleles [14] and to define the mechanisms underlying CD4 and MHC-I down-modulation by HIV and SIV Nefs [1518].

One of Kirchhoff`s main research interests was to elucidate the relative contribution of the many in vitro functions of Nef to viral replication and pathogenesis in vivo. To address this, he collaborated with Christiane Stahl-Hennig from the German Primate Research Center (Göttingen) to analyze the properties and evolution of specific mutant Nef SIVmac239 constructs in rhesus macaques. These studies provided evidence for the relevance of Nef-mediated modulation of CD4 [16, 17] and MHC-I [18, 19] as well as enhancement of viral infectivity and replication [16, 20] in vivo. However, they also showed that Nef’s interaction with the p21-activated kinase 2 (PAK2) is dispensable for AIDS progression in macaques [21, 22]. In cooperation with Leonid Margolis, he confirmed the importance of the HIV-1 accessory genes and Nef-mediated downmodulation of CD4 in ex vivo infected human lymphoid tissues [23, 24]. Together, these studies showed that Nef enhances viral replication and immune evasion in vivo by multiple genetically separable mechanisms and illustrated the enormous capacity of HIV-1 and SIVmac to “repair” attenuating point mutations in nef [25, 26] and to adapt to their respective host environment [27, 28].

Kirchhoff noted that most Nef functions are conserved between HIV-1, HIV-2 and SIV [2934] and showed that the HIV-1 nef gene can largely substitute for the SIVmac nef in infected rhesus macaques [35]. However, in cooperation with Beatrice H. Hahn and others, he also identified some interesting differences. For example, HIV-1 Nefs are usually less active than those of most SIVs or HIV-2 in downmodulating CXCR4 [36] and CD28 [37]. Most interestingly, he found that the Nef proteins of HIV-1 and its vpu containing SIV precursors generally lack the TCR-CD3 downmodulation function and render infected T cells hyper-responsive to stimulation, whereas HIV-2 and most SIV Nefs suppress T cell activation and apoptosis [3739]. Thus, it was tempting to speculate that this fundamental difference in Nef function might contribute to the chronic inflammation that drives progression to AIDS and is absent in some natural SIV infections [40]. In fact, inefficient downmodulation of TCR-CD3 by Nef (i.e. a more “HIV-1-like” phenotype) was associated with low numbers of CD4+ T cells in natural SIVsmm infection of sooty mangabeys [41] and in viremic HIV-2 infection [42]. Clearly, many host and viral factors play a role in the clinical outcome of HIV and SIV infection [43]. Nonetheless, his results support that the loss of Nef-mediated downmodulation of CD3 may have predisposed the retroviral lineage that resulted in the emergence of HIV-1 to higher pathogenicity.

Kirchhoff was curious to find out why the CD3 downmodulation function of Nef was specifically lost in primate lentiviruses encoding the viral vpu gene [37, 44]. Recent collaborative studies with Beatrice H. Hahn, Guido Silvestri and others provide first insights into the possible link between Vpu and Nef function. TCR-CD3 mediated T cell activation induces antiviral gene expression via NF-κB activation. Together with Daniel Sauter, a talented scientist in his lab, Kirchhoff showed that HIV-1 and its simian precursors utilize Vpu to prevent NF-κB activation [45]. Most other primate lentiviruses might achieve the same by Nef-mediated downmodulation of the TCR-CD3 receptor from the cell surface [37]. Notably, Nef proteins initially boost IKKβ-induced NF-κB activation irrespectively of their CD3 downmodulation function [45]. Thus, primate lentiviruses seem to use different strategies to boost NF-κB activation early during the viral life cycle to initiate proviral transcription and to suppress NF-κB-dependent antiviral gene expression at later stages. Finally, Kirchhoff observed that highly unusual CXCR4-tropic SIVsmm strains that cause almost complete loss of CD4+ T cells, lost their ability to downmodulate TCR-CD3 by evolving mutations disrupting the interaction of Nef with the CD3 ζ chain [46]. A possible explanation for this coevolution of Env and Nef function is that CD3 downmodulation may be advantageous for viral replication in activated CCR5 + memory T cells but not in naive CXCR4+ T cells. These studies thus provide insights into the interplay between different viral properties and may help to explain why HIV-1 more frequently switches to CXCR4 usage than SIV strains.

In 1998, Kirchhoff met Wolf-Georg Forssmann, who pioneered the isolation of endogenous bioactive peptides from complex libraries generated from human hemofiltrate. This source becomes available in thousands of liters from patients with renal failure and contains all peptides circulating in human blood. They decided to cooperate and a highly talented and tenacious diploma student (Jan Münch, who has meanwhile gained a full professorship in Ulm but lost his Rasta curls) started his work on the discovery of novel inhibitors of HIV infection. The initial studies identified a 20-residue C-proximal fragment of α1-antitrypsin, designated VIRus-Inhibitory Peptide (VIRIP) that inhibits HIV-1 infection by specific interaction with the viral gp41 fusion peptide [47]. An optimized derivative of this peptide was safe and effective in a phase I clinical trial [48] and current interdisciplinary research efforts aim at making it more active and orally available. Perhaps most strikingly, Kirchhoff and collaborators isolated a peptide from human semen forming amyloid fibrils that strongly enhance HIV infection [49]. Subsequent cooperative studies with Nadia Roan and Warner Greene showed that cleavage products of at least two abundant seminal proteins (prostatic acid phosphatase and semenogelin) form amyloid fibrils that boost HIV infection [50, 51] and are found in semen from healthy individuals [52]. They further showed that the enhancing effect of these amyloids depends on their positive charge [53] and characterized effective inhibitors [54, 55]. Recently, Münch and Kirchhoff also found that semen impairs the antiviral efficacy of microbicides [56] possibly explaining their poor efficacy in clinical trials. While the relevance of seminal amyloids for HIV transmission in vivo is still largely unclear [57], they even provided a basis for the development of nanofibrils as potent enhancers of retroviral gene transfer [58]. Thus, the strategy of utilizing peptide libraries from body fluids generated some unexpected and exciting results [59]. This is still continuing, e.g. with the recent discovery of a small fragment of serum albumin (EPI-X4) as an effective and highly specific CXCR4 antagonist that may represent a key regulator of CXCR4 signaling and an inhibitor of CXCR4-tropic HIV-1 strains in vivo [60].

Another key interest of Kirchhoff is the role of viral properties in the spread of HIV/AIDS. In cooperation with last year`s awardee, Paul Bieniasz, he showed that most SIVs use Nef to counteract the restriction factor tetherin [61]. However, Kirchhoff also found that the human tetherin ortholog is resistant to Nef due to a deletion in its cytoplasmic domain and that only the Vpu protein of pandemic HIV-1 group M evolved full activity against human tetherin [62]. In contrast, Vpus from rare group N viruses acquired only modest anti-tetherin activity and lost the CD4 degradation function [62] but are still evolving towards higher activity against tetherin [63]. Kirchhoff found that HIV-1 group P and O Vpus are inactive against human tetherin [64]. Recently, however, he noted that O-Nefs evolved the ability to target a different region in the cytoplasmic part to counteract human tetherin which helps to explain the epidemic spread of this group [65]. Kirchhoff also showed that HIV-1 can rapidly reacquire Nef-mediated anti-tetherin activity in its original chimpanzee host [66] and that tetherin antagonism significantly contributes to replication fitness and interferon resistance of transmitted-founder HIV-1 strains in CD4+ T cells [67]. Together with Daniel Sauter, he further demonstrated that the antiviral activity of tetherin [68] and the protective deletion in the human ortholog [69] have an ancient origin. Altogether, these data illustrate the importance of tetherin antagonism in the evolution and spread of HIV/AIDS. Finally, Kirchhoff is interested in the discovery of novel restriction factors. He joined forces with Amalio Telenti to perform genome-wide screens for cellular genes sharing features of those encoding known antiviral restriction factors [70]. Detailed characterization of one of them showed that guanylate binding protein 5 (GBP5) inhibits HIV-1 by interfering with Env function and can partly be evaded by increasing Env expression at the cost of Vpu function [71].

Kirchhoff received several awards including the Gottfried Wilhelm Leibniz award of the DFG (2009) and an ERC Advanced investigator grant (2012). He is currently an editor of the Journal of Virology and serves on various editorial and advisory boards. In 2012, Kirchhoff became cofounder of the competence center Ulm Peptide Pharmaceuticals (U-PEP). Besides his passion for table tennis that he is indulging daily after lunch for at least 1 h, he is highly interested in innovative interdisciplinary research and is co-applicant and one of four founding directors of Ulm University’s Centre of Quantum Biological Science (ZQB). In 2009, he was elected member of the German Academy of Sciences Leopoldina.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
BioMed Central

References

  1. Kirchhoff F, Jentsch KD, Bachmann B, Stuke A, Laloux C, Lüke W, Stahl-Hennig C, Schneider J, Nieselt K, Eigen M, Hunsmann G. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology. 1990;177:305–11.View ArticlePubMedGoogle Scholar
  2. Kirchhoff F, Jentsch KD, Stuke A, Mous J, Hunsmann G. Genomic divergence of an HIV 2 from a German AIDS patient probably infected in Mali. AIDS. 1990;4:847–57.View ArticlePubMedGoogle Scholar
  3. Kirchhoff F, Mori K, Desrosiers RC. The “V3” domain is a determinant of SIVmac cell tropism. J Virol. 1994;68:3682–92.PubMedPubMed CentralGoogle Scholar
  4. Kirchhoff F, Morrison HG, Desrosiers RC. Identification of changes in V3 compensating for defects in the C4 domain. Virology. 1995;213:179–89.View ArticlePubMedGoogle Scholar
  5. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258:1938–41.View ArticlePubMedGoogle Scholar
  6. Kirchhoff F, Kestler HW, Desrosiers RC. Upstream U3 sequences in SIV are selectively deleted in vivo in the absence of nef function. J Virol. 1994;68:2031–7.PubMedPubMed CentralGoogle Scholar
  7. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact nef sequences in a long-term, nonprogressing survivor of HIV-1 infection. N Engl J Med. 1995;332:228–32.View ArticlePubMedGoogle Scholar
  8. Kirchhoff F, Pöhlmann S, Hamacher M, Means RE, Kraus T, Überla K, Di Marzio P. SIVmac variants with differential T-cell and macrophage tropism use CCR5, and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol. 1997;71:6509–16.PubMedPubMed CentralGoogle Scholar
  9. Pöhlmann S, Stolte N, Münch J, Ten Haaft P, Heeney JL, Stahl-Hennig C, Kirchhoff F. BOB/GPR15 coreceptor usage has no significant effect on replication of simian immunodeficiency virus in vivo. J Inf Dis. 1999;180:1494–502.View ArticleGoogle Scholar
  10. Pöhlmann S, Benhur L, Meister S, Krumbiegel M, Leslie G, Doms RW, Kirchhoff F. Simian immunodeficiency virus utilizes human and sooty mangabey but not rhesus macaque STRL33 for efficient entry. J Virol. 2000;74:5075–82.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Sharron M, Pöhlmann S, Tsang M, Kirchhoff F, Doms RW, Lee B. Characterization of STRL33 expression and coreceptor activity. Blood. 2000;96:41–9.PubMedGoogle Scholar
  12. Pöhlmann S, Baribaud F, Lee B, Leslie G, Sanchez MD, Hiebenthal Millow K, Münch J, Kirchhoff F, Doms RW. DC SIGN interactions with HIV type 1, type 2, and SIV. J Virol. 2001;75:4664–72.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Pöhlmann S, Baribaud F, Lee B, Leslie G, Sanchez MD, Hiebenthal Millow K, Münch J, Kirchhoff F, Doms RW. DC SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions. J Virol. 2001;75:10523–6.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J. High frequency of defective nef alleles in a long-term survivor with nonprogressive HIV-1 infection. J Virol. 1996;70:7752–64.PubMedPubMed CentralGoogle Scholar
  15. Lock M, Greenberg ME, Iafrate AJ, Swigut T, Münch J, Kirchhoff F, Shohdy N, Skowronski J. Two elements target SIV Nef to the AP-2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis. EMBO J. 1999;172:2722–33.View ArticleGoogle Scholar
  16. Iafrate AJ, Carl S, Bronson S, Stahl-Hennig C, Hunsmann G, Skowronski J, Kirchhoff F. Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo. J Virol. 2000;74:9836–44.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Brenner M, Münch J, Schindler M, Wildum S, Stolte N, Stahl-Hennig C, Fuchs D, Mätz-Rensing K, Franz M, Heeney J, Ten Haaft P, Swigut T, Hrecka K, Skowronski J, Kirchhoff F. Importance of the N-distal AP-2 binding element in Nef for simian immunodeficiency virus replication and pathogenicity in rhesus macaques. J Virol. 2006;80:4469–81.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Swigut T, Iafrate AJ, Münch J, Kirchhoff F, Skowronski J. Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility antigen expression. J Virol. 2000;74:5691–701.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Münch J, Stolte N, Fuchs D, Stahl Hennig C, Kirchhoff F. Efficient class I MHC down regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J Virol. 2001;75:10532–6.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Schindler M, Münch J, Stahl-Hennig C, Skowronski J, Kirchhoff F. Comprehensive analysis of Nef functions selected in simian immunodeficiency virus-infected macaques. J Virol. 2004;78:10588–97.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lang SM, Iafrate AJ, Stahl-Hennig C, Kuhn EM, Nißlein T, Haupt M, Hunsmann G, Skowronski J, Kirchhoff F. Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques. Nat Med. 1997;3:860–5.View ArticlePubMedGoogle Scholar
  22. Carl S, Iafrate AJ, Lang SM, Stahl-Hennig C, Skowronski J, Kirchhoff F. Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol. 2000;74:4155–64.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Glushakova S, Münch J, Carl S, Greenough TC, Sullivan JL, Margolis L, Kirchhoff F. CD4 down modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4+ T cell depletion in human lymphoid tissue ex vivo. J Virol. 2001;75:10113–7.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Rücker E, Münch J, Grivel JC, Kirchhoff F, Margolis L. Vpr and Vpu are important for efficient HIV-1 replication and CD4+ T cell depletion in human lymphoid tissue ex vivo. J Virol. 2004;78:12689–93.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Carl S, Daniels R, Iafrate AJ, Easterbrook P, Greenough TC, Skowronski J, Kirchhoff F. Partial “repair” of defective NEF genes in a long term nonprogressor with human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181:132–40.View ArticlePubMedGoogle Scholar
  26. Carl S, Iafrate AJ, Stahl-Hennig C, Skowronski J, Kirchhoff F. The effect of the attenuating deletion and of sequence alterations evolving in vivo on simian immunodeficiency virus C8-Nef function. J Virol. 1999;73:2790–7.PubMedPubMed CentralGoogle Scholar
  27. Kirchhoff F, Carl S, Easterbrook PM, Troop M, Douglas N, Greenough TC, Hamacher M, Sullivan JL, Daniels RD. Sequence variations in HIV-1 Nef are associated with different stages of disease. J Virol. 1999;73:5497–508.PubMedPubMed CentralGoogle Scholar
  28. Carl S, Greenough TC, Krumbiegel M, Greenberg M, Skowronski J, Sullivan JL, Kirchhoff F. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol. 2001;75:3657–65.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Schindler M, Würfl S, Benaroch P, Greenough TC, Daniels RC, Easterbrook P, Brenner M, Münch J, Kirchhoff F. Down-modulation of mature MHC class II and up-regulation of invariant chain cell surface expression are well conserved functions of human and simian immunodeficiency virus nef-alleles. J Virol. 2003;77:10548–56.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Kirchhoff F, Schindler M, Bailer N, Renkema H, Saksela K, Knoop V, Müller-Trutwin MC, Santiago ML, Bibollet-Ruche F, Dittmar MT, Heeney JL, Hahn BH, Münch J. Nef proteins from SIVcpz-infected chimpanzees and HIV-1 group N and O-infected humans interact with the p21-activated kinase 2 and modulate cell surface expression of various human receptors. J Virol. 2004;78:6864–74.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Münch J, Schindler M, Wildum S, Rücker E, Bailer N, Knoop V, Novembre FJ, Kirchhoff F. Primary SIVsm and HIV-2 Nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication. J Virol. 2005;79:10547–60.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Münch J, Rajan D, Schindler M, Rücker E, Novembre FJ, Nerrienet E, Müller-Trutwin MC, Peeters M, Hahn BH, Kirchhoff F. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol. 2007;81:13852–64.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Specht A, DeGottardi QM, Schindler M, Hahn BH, Evans DT, Kirchhoff F. Selective downmodulation of HLA-A and -B by Nef alleles from different groups of primate lentiviruses. Virology. 2008;373:229–37.View ArticlePubMedGoogle Scholar
  34. Heigele A, Schindler M, Gnanadurai C, Leonard J, Collins K, Kirchhoff F. Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins. J Virol. 2012;86:36–48.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Kirchhoff F, Münch J, Carl S, Stolte N, Mätz-Rensing K, Fuchs D, Ten Haaft P, Heeney JL, Swigut T, Skowronski J, Stahl Hennig C. The human immunodeficiency virus type 1 nef gene can to a large extent substitute for the simian immunodeficiency virus nef in vivo. J Virol. 1999;73:8371–83.PubMedPubMed CentralGoogle Scholar
  36. Hrecka K, Swigut T, Schindler M, Kirchhoff F, Skowronski J. Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to SDF-1 chemokine. J Virol. 2005;79:10650–9.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006;125:1055–67.View ArticlePubMedGoogle Scholar
  38. Arhel N, Clauss K, Nienhaus GU, Kirchhoff F. The inability to disrupt the immunological synapse distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest. 2009;119:2965–75.PubMedPubMed CentralGoogle Scholar
  39. Yu H, Khalid M, Heigele A, Schmökel J, Usmani S, van der Merwe J, Münch J, Silvestri J, Kirchhoff F. Lentiviral Nef proteins manipulate T cells in a subset-specific manner. J Virol. 2015;89:1986–2001.View ArticlePubMedGoogle Scholar
  40. Kirchhoff F. Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution? Nat Rev Microbiol. 2009;7:467–76.PubMedGoogle Scholar
  41. Schindler M, Schmökel J, Specht A, Li H, Münch J, Khalid M, Sodora DL, Hahn BH, Silvestri G, Kirchhoff F. Inefficient Nef-mediated downmodulation of CD3 and MHC-I correlates with loss of CD4+ T cells in natural SIV infection. PLoS Pathog. 2008;4:e1000107.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Khalid M, Yu H, Sauter D, Usmani S, Schmokel J, Feldman J, Gruters R, van der Ende M, Geyer M, Jones S, Osterhaus A, Kirchhoff F. Efficient Nef-mediated down-modulation of TCR-CD3 and CD28 is associated with High CD4+ T cell counts in viremic HIV-2 infection. J Virol. 2012;86:4906–20.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur S, Kirchhoff F, Muller-Trutwin M, Pandrea IV, Schmitz JE, Silvestri G. Towards an AIDS vaccine: lessons from natural SIV infections of African nonhuman primate hosts. Nat Med. 2009;15:861–5.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Schmökel J, Sauter D, Schindler M, Leendertz FH, Bailes E, Dazza MC, Saragosti S, Bibollet-Ruche F, Peeters M, Hahn BH, Kirchhoff F. The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J Virol. 2011;85:742–52.View ArticlePubMedGoogle Scholar
  45. Sauter D, Hotter D, Van Driessche B, Stürzel CM, Kluge SF, Wildum S, Yu H, Baumann B, Wirth T, Hahn BH, Van Lint C, Kirchhoff F. Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep. 2015;10:586–99.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Schmökel J, Li H, Shabir A, Yu H, Geyer M, Silvestri G, Sodora DL, Hahn BH, Kirchhoff F. Link between primate lentiviral coreceptor usage and Nef function. Cell Rep. 2013;5:997–1009.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer T, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann W-G, Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 2007;129:263–375.View ArticlePubMedGoogle Scholar
  48. Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Giménez-Gallego G, Hirsch J, Jiménez-Barbero J, Meyer-Olson D, Münch J, Pérez-Castells J, Ständker L, Kirchhoff F, Schmidt RE. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med. 2010;2(63):63re3.View ArticlePubMedGoogle Scholar
  49. Münch J, Rücker E, Ständker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Giménez-Gallego G, Cuevas-Sánchez G, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel J-C, Margolis L, Keppler OT, Forssmann W-G, Kirchhoff F. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007;131:1059–71.View ArticlePubMedGoogle Scholar
  50. Roan NR, Müller JA, Liu H, Chu S, Arnold F, Stürzel CM, Walther P, Dong M, Witkowska HE, Kirchhoff F, Münch J, Greene WC. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe. 2011;10:541–50.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Arnold F, Schnell J, Zirafi O, Stürzel C, Meier C, Weil T, Ständker L, Forssmann WG, Roan NR, Greene WC, Kirchhoff F, Münch J. Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J Virol. 2012;86:1244–9.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Usmani SM, Zirafi O, Müller JA, Sandi-Monroy NL, Yadav JK, Meier C, Weil T, Roan NR, Greene WC, Walther P, Nilsson KP, Hammarström P, Wetzel R, Pilcher CD, Gagsteiger F, Fändrich M, Kirchhoff F, Münch J. Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Nat Commun. 2014;5:3508.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Roan NR, Münch J, Arhel N, Mothes W, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC. The cationic properties of SEVI underlie its ability to enhance HIV infection. J Virol. 2009;83:73–80.View ArticlePubMedGoogle Scholar
  54. Roan NR, Sowinski S, Münch J, Kirchhoff F, Greene WC. Semen-mediated enhancement of HIV-1 infection is inhibited by surfen, an antagonist of heparan sulfate proteoglycans. J Biol Chem. 2009;285:1861–9.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Lump E, Castellano LM, Meier C, Seeliger J, Erwin N, Sperlich B, Stürzel CM, Usmani S, Hammond RM, von Einem J, Gerold G, Kreppel F, Bravo-Rodriguez K, Pietschmann T, Holmes VM, Palesch D, Zirafi O, Weissman D, Sowislok A, Wettig B, Heid C, Kirchhoff F, Weil T, Klärner FG, Schrader T, Bitan G, Sanchez-Garcia E, Winter R, Shorter J, Münch J. A molecular tweezer antagonizes seminal amyloids and HIV infection. Elife. 2015. doi:10.7554/eLife.05397.PubMedPubMed CentralGoogle Scholar
  56. Zirafi O, Kim KA, Roan NR, Kluge SF, Müller JA, Jiang S, Mayer B, Greene WC, Kirchhoff F, Münch J. HIV enhancing activity of semen impairs the antiviral efficacy of microbicides. Sci Transl Med. 2014;6:262ra157.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Münch J, Sauermann U, Yolamanova M, Raue K, Stahl-Hennig C, Kirchhoff F. Effect of semen and seminal amyloid on vaginal transmission of simian immunodeficiency virus. Retrovirology. 2013;10:148.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Yolamanova M, Meier C, Shaytan AK, Vas V, Bertoncini CW, Arnold F, Zirafi O, Usmani SM, Müller JA, Sauter D, Goffinet C, Palesch D, Walther P, Roan NR, Geiger H, Lunov O, Simmet T, Bohne J, Schrezenmeier H, Schwarz K, Ständker L, Forssmann WG, Salvatella X, Khalatur PG, Khokhlov AR, Knowles TP, Weil T, Kirchhoff F, Münch J. Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol. 2013;8:130–6.View ArticlePubMedGoogle Scholar
  59. Münch J, Ständker L, Forssmann WG, Kirchhoff F. Discovery of modulators of HIV-1 infection from the human peptidome. Nat Rev Microbiol. 2014;12:715–22.View ArticlePubMedGoogle Scholar
  60. Zirafi O, Kim KA, Ständker L, Mohr KB, Sauter D, Heigele A, Kluge SF, Wiercinska E, Chudziak D, Richter R, Moepps B, Gierschik P, Vas V, Geiger H, Lamla M, Weil T, Burster T, Zgraja A, Daubeuf F, Frossard N, Hachet-Haas M, Heunisch F, Reichetzeder C, Galzi JL, Pérez-Castells J, Canales-Mayordomo A, Jiménez-Barbero J, Giménez-Gallego G, Schneider M, Shorter J, Telenti A, Hocher B, Forssmann WG, Bonig H, Kirchhoff F, Münch J. Discovery and characterization of an endogenous CXCR4 antagonist. Cell Rep. 2015;11:737–47.View ArticlePubMedGoogle Scholar
  61. Zhang F, Wilson SJ, Langford W, Virgen B, Gregory D, Johnson M, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbes. 2009;6:54–67.View ArticleGoogle Scholar
  62. Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim K-J, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn G, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function during the evolution of pandemic and non-pandemic HIV-1 strains. Cell Host Microbe. 2009;6:409–21.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog. 2012;8:e1003093.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Sauter D, Hué S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F, Gupta RK. HIV-1 Group P is unable to antagonize human tetherin Vpu, Env or Nef. Retrovirology. 2011;8:103.View ArticlePubMedPubMed CentralGoogle Scholar
  65. Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, Bibollet-Ruche F, Plenderleith LJ, Peeters M, Geyer M, Sharp PM, Fackler OT, Hahn BH, Kirchhoff F. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe. 2014;16:639–50.View ArticlePubMedPubMed CentralGoogle Scholar
  66. Götz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A, Geyer M, Bibollet-Ruche F, Learn GH, Fackler OT, Hahn BH, Kirchhoff F. Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe. 2012;12:373–80.View ArticlePubMedPubMed CentralGoogle Scholar
  67. Kmiec D, Iyer SS, Stürzel CM, Sauter D, Hahn BH, Kirchhoff F. Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. mBio (accepted).Google Scholar
  68. Heusinger E, Kluge S, Kirchhoff F, Sauter D. Early vertebrate evolution of the host restriction factor tetherin. J Virol. 2015;89:12154–65.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Sauter D, Vogl M, Kirchhoff F. Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses. Hum Mutat. 2011;32:1243–5.View ArticlePubMedGoogle Scholar
  70. McLaren PJ, Gawanbacht A, Pyndiah N, Krapp C, Hotter D, Kluge SF, Götz N, Heilmann J, Mack K, Sauter D, Thompson D, Perreaud J, Rausell A, Munoz M, Ciuffi A, Kirchhoff F, Telenti A. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology. 2015;16:41.View ArticleGoogle Scholar
  71. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Stürzel CM, Mack K, Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe. 2016;19:504–14.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2016

Advertisement